1	Decrease	_	NN	_	_	5	VMOD	_	_
2	in	_	IN	_	_	1	NMOD	_	_
3	c-Myc	_	NN	_	_	4	NMOD	_	_
4	activity	_	NN	_	_	2	PMOD	_	_
5	enhances	_	VBZ	_	_	0	ROOT	_	_
6	cancer	_	NN	_	_	8	NMOD	_	_
7	cell	_	NN	_	_	8	NMOD	_	_
8	sensitivity	_	NN	_	_	5	VMOD	_	_
9	to	_	TO	_	_	8	NMOD	_	_
10	vinblastine	_	NN	_	_	9	PMOD	_	_
11	.	_	.	_	_	5	P	_	_
		
1	The	_	DT	_	_	3	NMOD	_	_
2	c-myc	_	NN	_	_	3	NMOD	_	_
3	oncogene	_	NN	_	_	4	VMOD	_	_
4	encodes	_	VBZ	_	_	0	ROOT	_	_
5	for	_	IN	_	_	4	VMOD	_	_
6	a	_	DT	_	_	8	NMOD	_	_
7	transcriptional	_	JJ	_	_	8	NMOD	_	_
8	factor	_	NN	_	_	5	PMOD	_	_
9	involved	_	VBN	_	_	8	APPO	_	_
10	in	_	IN	_	_	9	VMOD	_	_
11	many	_	JJ	_	_	13	NMOD	_	_
12	cellular	_	JJ	_	_	13	NMOD	_	_
13	processes	_	NNS	_	_	10	PMOD	_	_
14	such	_	JJ	_	_	15	DEP	_	_
15	as	_	IN	_	_	13	NMOD	_	_
16	proliferation	_	NN	_	_	15	PMOD	_	_
17	,	_	,	_	_	16	P	_	_
18	differentiation	_	NN	_	_	16	COORD	_	_
19	and	_	CC	_	_	18	COORD	_	_
20	apoptosis	_	NN	_	_	19	CONJ	_	_
21	.	_	.	_	_	4	P	_	_
		
1	According	_	VBG	_	_	18	VC	_	_
2	to	_	TO	_	_	1	VMOD	_	_
3	these	_	DT	_	_	5	NMOD	_	_
4	different	_	JJ	_	_	5	NMOD	_	_
5	functions	_	NNS	_	_	2	PMOD	_	_
6	,	_	,	_	_	18	P	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	role	_	NN	_	_	18	VMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	c-Myc	_	NN	_	_	11	NMOD	_	_
11	protein	_	NN	_	_	9	PMOD	_	_
12	in	_	IN	_	_	8	NMOD	_	_
13	cellular	_	JJ	_	_	14	NMOD	_	_
14	sensitivity	_	NN	_	_	12	PMOD	_	_
15	to	_	TO	_	_	14	NMOD	_	_
16	anti-cancer	_	JJ	_	_	17	NMOD	_	_
17	drugs	_	NNS	_	_	15	PMOD	_	_
18	is	_	VBZ	_	_	0	ROOT	_	_
19	controversial	_	JJ	_	_	18	VMOD	_	_
20	.	_	.	_	_	18	P	_	_
		
1	We	_	PRP	_	_	2	VMOD	_	_
2	defined	_	VBD	_	_	0	ROOT	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	role	_	NN	_	_	2	VMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	c-Myc	_	NN	_	_	5	PMOD	_	_
7	in	_	IN	_	_	4	NMOD	_	_
8	cancer	_	NN	_	_	10	NMOD	_	_
9	cell	_	NN	_	_	10	NMOD	_	_
10	sensitivity	_	NN	_	_	7	PMOD	_	_
11	to	_	TO	_	_	10	NMOD	_	_
12	vinblastine	_	NN	_	_	11	PMOD	_	_
13	(	_	(	_	_	14	P	_	_
14	VLB	_	NN	_	_	12	PRN	_	_
15	)	_	)	_	_	14	P	_	_
16	using	_	VBG	_	_	12	APPO	_	_
17	human	_	JJ	_	_	20	NMOD	_	_
18	colon	_	NN	_	_	20	NMOD	_	_
19	cancer	_	NN	_	_	20	NMOD	_	_
20	cells	_	NNS	_	_	16	VMOD	_	_
21	:	_	:	_	_	20	P	_	_
22	LoVo	_	NN	_	_	20	APPO	_	_
23	wild-type	_	JJ	_	_	22	AMOD	_	_
24	or	_	CC	_	_	22	COORD	_	_
25	transfected	_	VBN	_	_	24	CONJ	_	_
26	with	_	IN	_	_	25	AMOD	_	_
27	a	_	DT	_	_	28	NMOD	_	_
28	plasmid	_	NN	_	_	26	PMOD	_	_
29	containing	_	VBG	_	_	28	APPO	_	_
30	the	_	DT	_	_	33	NMOD	_	_
31	human	_	JJ	_	_	33	NMOD	_	_
32	c-myc	_	NN	_	_	33	NMOD	_	_
33	gene	_	NN	_	_	29	VMOD	_	_
34	in	_	IN	_	_	29	VMOD	_	_
35	antisense	_	JJ	_	_	36	NMOD	_	_
36	orientation	_	NN	_	_	34	PMOD	_	_
37	(	_	(	_	_	38	P	_	_
38	LoVo-mycANS	_	NN	_	_	36	PRN	_	_
39	)	_	)	_	_	38	P	_	_
40	.	_	.	_	_	2	P	_	_
		
1	Analysis	_	NN	_	_	5	VMOD	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	VLB	_	NN	_	_	4	NMOD	_	_
4	cytotoxicity	_	NN	_	_	2	PMOD	_	_
5	demonstrated	_	VBD	_	_	0	ROOT	_	_
6	a	_	DT	_	_	8	NMOD	_	_
7	3-fold	_	JJ	_	_	8	NMOD	_	_
8	increase	_	NN	_	_	5	VMOD	_	_
9	in	_	IN	_	_	8	NMOD	_	_
10	VLB	_	NN	_	_	11	NMOD	_	_
11	sensitivity	_	NN	_	_	9	PMOD	_	_
12	in	_	IN	_	_	8	NMOD	_	_
13	LoVo-mycANS	_	NN	_	_	14	NMOD	_	_
14	cells	_	NNS	_	_	12	PMOD	_	_
15	.	_	.	_	_	5	P	_	_
		
1	Comparison	_	NN	_	_	4	VMOD	_	_
2	between	_	IN	_	_	1	NMOD	_	_
3	cells	_	NNS	_	_	2	PMOD	_	_
4	revealed	_	VBD	_	_	0	ROOT	_	_
5	different	_	JJ	_	_	7	NMOD	_	_
6	apoptosis	_	NN	_	_	7	NMOD	_	_
7	kinetics	_	NNS	_	_	4	VMOD	_	_
8	:	_	:	_	_	4	P	_	_
9	accumulation	_	NN	_	_	19	VMOD	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	cells	_	NNS	_	_	10	PMOD	_	_
12	in	_	IN	_	_	11	NMOD	_	_
13	sub-G1	_	JJ	_	_	14	NMOD	_	_
14	phase	_	NN	_	_	12	PMOD	_	_
15	and	_	CC	_	_	14	COORD	_	_
16	poly(ADP-ribose)	_	JJ	_	_	17	NMOD	_	_
17	polymerase	_	NN	_	_	18	NMOD	_	_
18	cleavage	_	NN	_	_	15	CONJ	_	_
19	occurred	_	VBD	_	_	4	COORD	_	_
20	earlier	_	RBR	_	_	19	VMOD	_	_
21	in	_	IN	_	_	19	VMOD	_	_
22	LoVo-mycANS	_	NN	_	_	21	PMOD	_	_
23	.	_	.	_	_	4	P	_	_
		
1	Then	_	RB	_	_	4	VMOD	_	_
2	,	_	,	_	_	4	P	_	_
3	we	_	PRP	_	_	4	VMOD	_	_
4	demonstrated	_	VBD	_	_	0	ROOT	_	_
5	a	_	DT	_	_	9	NMOD	_	_
6	mitochondrial	_	JJ	_	_	9	NMOD	_	_
7	membrane	_	NN	_	_	9	NMOD	_	_
8	potential	_	NN	_	_	9	NMOD	_	_
9	disruption	_	NN	_	_	4	VMOD	_	_
10	followed	_	VBN	_	_	9	APPO	_	_
11	by	_	IN	_	_	10	VMOD	_	_
12	cytochrome	_	NN	_	_	14	NMOD	_	_
13	c	_	NN	_	_	14	NMOD	_	_
14	release	_	NN	_	_	11	PMOD	_	_
15	that	_	WDT	_	_	16	VMOD	_	_
16	indicates	_	VBZ	_	_	14	NMOD	_	_
17	the	_	DT	_	_	18	NMOD	_	_
18	involvement	_	NN	_	_	16	VMOD	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	mitochondria	_	NN	_	_	19	PMOD	_	_
21	in	_	IN	_	_	18	NMOD	_	_
22	this	_	DT	_	_	25	NMOD	_	_
23	apoptotic	_	JJ	_	_	25	NMOD	_	_
24	signaling	_	NN	_	_	25	NMOD	_	_
25	pathway	_	NN	_	_	21	PMOD	_	_
26	.	_	.	_	_	4	P	_	_
		
1	This	_	DT	_	_	3	NMOD	_	_
2	earlier	_	JJR	_	_	3	NMOD	_	_
3	apoptosis	_	NN	_	_	4	VMOD	_	_
4	was	_	VBD	_	_	0	ROOT	_	_
5	accompanied	_	VBN	_	_	4	VC	_	_
6	by	_	IN	_	_	5	VMOD	_	_
7	a	_	DT	_	_	9	NMOD	_	_
8	Bcl-2	_	NN	_	_	9	NMOD	_	_
9	decrease	_	NN	_	_	6	PMOD	_	_
10	and	_	CC	_	_	9	COORD	_	_
11	a	_	DT	_	_	13	NMOD	_	_
12	p53	_	NN	_	_	13	NMOD	_	_
13	increase	_	NN	_	_	10	CONJ	_	_
14	.	_	.	_	_	4	P	_	_
		
1	In	_	IN	_	_	9	VMOD	_	_
2	conclusion	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	9	P	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	decrease	_	NN	_	_	9	VMOD	_	_
6	in	_	IN	_	_	5	NMOD	_	_
7	c-Myc	_	NN	_	_	8	NMOD	_	_
8	expression	_	NN	_	_	6	PMOD	_	_
9	enhanced	_	VBD	_	_	0	ROOT	_	_
10	the	_	DT	_	_	12	NMOD	_	_
11	VLB	_	NN	_	_	12	NMOD	_	_
12	sensitivity	_	NN	_	_	9	VMOD	_	_
13	,	_	,	_	_	9	P	_	_
14	triggering	_	VBG	_	_	9	VMOD	_	_
15	earlier	_	JJR	_	_	16	NMOD	_	_
16	apoptosis	_	NN	_	_	14	VMOD	_	_
17	through	_	IN	_	_	14	VMOD	_	_
18	induction	_	NN	_	_	17	PMOD	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	the	_	DT	_	_	22	NMOD	_	_
21	intrinsic	_	JJ	_	_	22	NMOD	_	_
22	pathway	_	NN	_	_	19	PMOD	_	_
23	.	_	.	_	_	9	P	_	_
		
1	Thus	_	RB	_	_	5	VMOD	_	_
2	,	_	,	_	_	5	P	_	_
3	c-myc	_	NN	_	_	4	NMOD	_	_
4	induction	_	NN	_	_	5	VMOD	_	_
5	is	_	VBZ	_	_	0	ROOT	_	_
6	a	_	DT	_	_	8	NMOD	_	_
7	resistance	_	NN	_	_	8	NMOD	_	_
8	factor	_	NN	_	_	5	VMOD	_	_
9	and	_	CC	_	_	5	COORD	_	_
10	our	_	PRP$	_	_	11	NMOD	_	_
11	findings	_	NNS	_	_	12	VMOD	_	_
12	suggest	_	VBP	_	_	9	CONJ	_	_
13	that	_	IN	_	_	12	VMOD	_	_
14	tumors	_	NNS	_	_	21	VMOD	_	_
15	carrying	_	VBG	_	_	14	APPO	_	_
16	low	_	JJ	_	_	17	NMOD	_	_
17	levels	_	NNS	_	_	15	VMOD	_	_
18	of	_	IN	_	_	17	NMOD	_	_
19	c-Myc	_	NN	_	_	20	NMOD	_	_
20	protein	_	NN	_	_	18	PMOD	_	_
21	could	_	MD	_	_	13	SUB	_	_
22	be	_	VB	_	_	21	VC	_	_
23	more	_	RBR	_	_	24	AMOD	_	_
24	responsive	_	JJ	_	_	22	VMOD	_	_
25	to	_	TO	_	_	24	AMOD	_	_
26	vinca	_	NN	_	_	27	NMOD	_	_
27	alkaloids	_	NNS	_	_	25	PMOD	_	_
28	treatment	_	NN	_	_	25	PMOD	_	_
29	.	_	.	_	_	5	P	_	_
		
1	Moreover	_	RB	_	_	12	VMOD	_	_
2	,	_	,	_	_	12	P	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	downregulation	_	NN	_	_	12	VMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	c-myc	_	NN	_	_	7	NMOD	_	_
7	oncogene	_	NN	_	_	5	PMOD	_	_
8	by	_	IN	_	_	4	NMOD	_	_
9	an	_	DT	_	_	11	NMOD	_	_
10	antisense	_	JJ	_	_	11	NMOD	_	_
11	strategy	_	NN	_	_	8	PMOD	_	_
12	might	_	MD	_	_	0	ROOT	_	_
13	represent	_	VB	_	_	12	VC	_	_
14	a	_	DT	_	_	16	NMOD	_	_
15	useful	_	JJ	_	_	16	NMOD	_	_
16	goal	_	NN	_	_	13	VMOD	_	_
17	for	_	IN	_	_	16	NMOD	_	_
18	improving	_	VBG	_	_	17	PMOD	_	_
19	the	_	DT	_	_	20	NMOD	_	_
20	efficacy	_	NN	_	_	18	VMOD	_	_
21	of	_	IN	_	_	20	NMOD	_	_
22	this	_	DT	_	_	25	NMOD	_	_
23	anti-neoplastic	_	JJ	_	_	25	NMOD	_	_
24	drug	_	NN	_	_	25	NMOD	_	_
25	family	_	NN	_	_	21	PMOD	_	_
26	.	_	.	_	_	12	P	_	_
		
